Search Results - "Gabrail, N."

Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer by Cohen, S.J., Punt, C.J.A., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M.A., Mitchell, E., Miller, M.C., Doyle, G.V., Tissing, H., Terstappen, L.W.M.M., Meropol, N.J.

“…Background: We demonstrated that circulating tumor cell (CTC) number at baseline and follow-up is an independent prognostic factor in metastatic colorectal…”
Get full text

Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer by Aggarwal, C., Meropol, N.J., Punt, C.J., Iannotti, N., Saidman, B.H., Sabbath, K.D., Gabrail, N.Y., Picus, J., Morse, M.A., Mitchell, E., Miller, M.C., Cohen, S.J.

“…We previously reported results of a prospective trial evaluating the significance of circulating tumor cells (CTCs) in patients with metastatic colorectal…”
Get full text

HALO 107-201: A phase Ib, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC) by Baumgart, M., Muhsin, M., Wu, W., Gabrail, N.

Get full text

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis by Pardanani, A, Tefferi, A, Jamieson, C, Gabrail, N Y, Lebedinsky, C, Gao, G, Liu, F, Xu, C, Cao, H, Talpaz, M

“…In this phase 2 open-label randomized study, 31 patients with intermediate-2 or high-risk myelofibrosis received fedratinib 300, 400 or 500 mg once daily in…”
Get full text

Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors by Garon, E.B., Wong, D.J., Schneider, J.G., Aljumaily, R., Korn, W.M., Patel, M.R., Autio, K.A., Papadopoulos, K.P., Naing, A., Gabrail, N., Munster, P.N., Goldman, J., Hung, A., Oft, M., Leveque, J., Spigel, D.R.

Get full text

330 First-in-man study of gemcitabine hydrochloride oral formulation (D07001-F4) in patients with malignant tumors by Gabrail, N, Ghamande, S, Silverman, M, Smith, C, Ho, H.L, Huang, C.T, Hsueh, S.P, Lin, C.L

Get full text

P1334 : A multicentre, randomised, open-label study comparing the efficacy and safety of two doses of Doxorubicin TransdrugTM to best standard of care in patients with advanced Hepatocellular Carcinoma (HCC) after sorafenib. The relive study by Merle, P, Pelletier, G, Habersetzer, F, Luca Frassineti, G, Pageaux, G.-P, Borbath, I, Gérolami, R, Sánchez Antolín, G, Bronowicki, J.-P, Horváth, Z, Touchefeu, Y, Maieron, A, Wege, H, Breder, V, Gabrail, N, Vasseur, B, Attali, P, Blanc, J.-F

Get full text

3011 POSTER 18-Month Safety Analysis of Fentanyl Pectin Nasal Spray (FPNS) in Patients With Breakthrough Pain in Cancer (BTPC) by Torres, L, Lynch, L, Revnic, J, Ramos, M, Reale, C, Gabrail, N

Get full text

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study by Prada, C.P, Shain, K.H, Voorhees, P, Gabrail, N, Abidi, M, Zonder, J, Boccia, R, Richardson, P.G, Neuman, L, Wong, H, Dixon, S, Hari, P

Get full text

Abstract No. 147: A phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in central venous catheters: TROPICS 1 by Gabrail, N, Sandler, E, Charu, V, Anas, N, Lim, E, Blaney, M, Ashby, M, Gillespie, B, Begelman, S

Get full text

The Keynote B36 (EF-36) Pilot Study of Tumor Treating Fields (TTFields) Therapy with pembrolizumab as First-Line Treatment of PD-L1-Positive, Advanced or Metastatic Non-Small Cell Lung Cancer by Chen, A.B., Kotecha, R., Chaney, M., Balestrieri, K., Gabrail, N., Langer, C.

Get full text

467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial by Garon, E.B, Neidhart, J, Neidhart, J.D, Kabbinavar, F, Gabrail, N, de Oliveira, M. Ribeiro, Lu, S.P, Balkissoon, J

Get full text

1439PHALO 107-201: A phase Ib, open-label, multicenter study of pegvorhyaluronidase alfa (PEGPH20) + docetaxel in patients (pts) with recurrent locally advanced or metastatic non-small cell lung cancer (NSCLC) by Baumgart, M, Muhsin, M, Wu, W, Gabrail, N

Get full text

A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain by Portenoy, Russell K., Burton, Allen W., Gabrail, Nashat, Taylor, Donald

“…This randomized, double-blind, crossover study assessed the efficacy and tolerability of a new rapid onset nasal fentanyl formulation (Fentanyl Pectin Nasal…”
Get full text

A Phase 1 Dose-escalation and Expansion Study of CUE-101, Given As Monotherapy in 3rd Line and in Combination with Pembrolizumab in 1st Line Recurrent/Metastatic (R/M) HPV16+ Head and Neck Cancer Patients by Colevas, A.D., Chung, C.H., Adkins, D., Rodriguez, C.P., Park, J.C., Gibson, M.K., Sukari, A., Burtness, B., Johnson, F.M., Julian, R.A., Saba, N.F., Worden, F., Dunn, L., Seiwert, T.Y., Jotte, R.M., Haddad, R., Gabrail, N., Bauman, J., Margossian, S.P., Pai, S.I.

“…Immuno-STATs are T cell engagers which activate tumor-antigen specific CD8+ T cells via targeted delivery of cytokines. CUE-101 is a human leukocyte antigen…”
Get full text

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens by Niesvizky, Ruben, Flinn, Ian W, Rifkin, Robert, Gabrail, Nashat, Charu, Veena, Clowney, Billy, Essell, James, Gaffar, Yousuf, Warr, Thomas, Neuwirth, Rachel, Zhu, Yanyan, Elliott, Jennifer, Esseltine, Dixie-Lee, Niculescu, Liviu, Reeves, James

“…The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bortezomib-based regimens in transplantation-ineligible patients with…”
Get full text

898TiP - The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza) by Vogelzang, N.J., Gabrail, N., Malik, Z., Volterra, F., Nordquist, L.T., Levin, R., Zhang, P., Zhou, K.

“…Prostate cancer is the most common malignant tumor in men and is the second leading cause of cancer-related deaths in men. Recently there are several 2nd…”
Get full text

The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza) by Vogelzang, N.J., Gabrail, N., Malik, Z., Volterra, F., Nordquist, L.T., Levin, R., Zhang, P., Zhou, K.

Get full text

22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results by Qing, Z., Gabrail, N., Uprety, D., Rotow, J., Han, B., Jänne, P.A., Nagasaka, M., Zheng, M., Zhang, Y., Yang, G., Sun, Y., Peng, B., Wu, Y-L.

Get full text

689P DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study by Marathe, O., Cheng, Y., Spira, A.I., Hamilton, E.P., Rubinstein, M.M., Dong, X., Li, L., Lv, D., Shi, J., Gabrail, N., Amin, H., Wu, C., Zhu, Z., Qiu, Y., Gu, V., Qiu, X., Shi, R., Liu, L., Miao, P., Ueno, N.T.

Get full text